



a certified prescriber of a medical device
for the first-line treatment of unresectable
malignant pleural mesothelioma (MPM)

MPM is a rare but aggressive cancer with approximately 3000 newly diagnosed cases and 2500 deaths in the United States each year.¹ It is commonly associated with a delayed onset of up to 40 years following occupational or environmental asbestos exposure.² Most patients present with nonspecific symptoms which may mimic other respiratory disease and are diagnosed in advanced stage; this diagnosis is associated with a life expectancy of about 7 to 12 months with supportive care or chemotherapy, respectively.² There is an unmet need for additional treatment options.

As part of my clinical practice, I am certified to prescribe a medical device indicated for the treatment of newly diagnosed MPM—Tumor Treating Fields in combination with pemetrexed and platinum-based chemotherapy.

To learn more about this treatment option and how it might benefit your patients, please contact me at

Kind regards,

REFERENCES:

1. Beebe-Dimmer JL, et al. *Clin Epidemiol*. 2016;8:743-750. doi: 10.2147/CLEP.S105396.
2. Bianco A, et al. *J Thorac Dis*. 2018;10(Suppl 2):S253-S261.